The company's consolidated net profit is down by 45 per cent to Rs 395 cr as opposed to the corresponding quarter in the previous year Rs 722.81 cr. The specialty pharmaceutical company's consolidated net sales has gone down by 10 per cent to Rs 1134 cr. The consolidated net profit in the corresponding quarter of the previous year was Rs 1257 cr.
However, in the domestic market revenue from Formulations segment increased 81 per cent to Rs.652.58 cr from Rs.361.54 cr in the year-ago quarter. But the revenue from the bulk segment amounted to Rs.21.16 cr, down 3 per cent from Rs.21.76 cr in the previous Q4.
In the international markets revenue from Formulations segment dipped 57 per cent to Rs.351.95 cr from Rs.824.11 cr. However, the revenue from Bulk segment totaled Rs.130.49 cr, up 85 per cent from Rs.70.53 crore.
And for the company's subsidiary, Caraco Pharmaceutical Industries Ltd's, sales for the quarter were lower by 67 per cent.